Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02796651 · ClinicalTrials.gov registry record · Phase 2
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
NCT02796651 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 132 participants.
The verdict
NCT02796651, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
Study Summary
To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized formoterol fumarate (20 μg and 40 μg).
Interventions
- DRUG Formoterol furmarate (20 μg)
- DRUG Formoterol fumarate (6 μg)
- DRUG Placebo for formoterol fumarate
- DRUG Formoterol fumarate (12 μg)
- DRUG Formoterol fumarate (40 μg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2016-06-30 |
| Est. Completion | 2016-12-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02796651
The ClinicalTrials.gov registry entry for NCT02796651 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Formoterol furmarate (20 μg) is the first listed.
NCT02796651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02796651 about?
NCT02796651 is a clinical study titled "Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)". To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized formoterol fumarate (20 μg and 40 μg).
What is the current status of trial NCT02796651?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2016-06-30. Estimated completion is 2016-12-07.
What interventions are being tested in trial NCT02796651?
The interventions under investigation include: Formoterol furmarate (20 μg) (DRUG), Formoterol fumarate (6 μg) (DRUG), Placebo for formoterol fumarate (DRUG), Formoterol fumarate (12 μg) (DRUG), Formoterol fumarate (40 μg) (DRUG).
Who is sponsoring clinical trial NCT02796651?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.